risks of glp 1 inhibitors The expanding role GLP-1 receptor agonists: a narrative review of current evidence and future directions Exploring the Side Effects of
Description
Significant reductions in BMI (1.71 [2.74, 0.67]
Credits: istock.org
Secondary outcomes included time below and above the therapeutic range and INR variability
Our lawsuit lawyers fight for justice and compensation
Glucagon-like peptide-1 (GLP-1)-based therapiesincluding dual and triple agonists, oral agents, and longer acting formulationswill be a recurring topic.
(Sun F et al
